The second phase clinical trial of duloxetine enteric-coated tablets for the treatment of the maj or depressive disorder

• Published in: Sichuan Jingshen Weisheng Vol. 27; no. 2; p. 132
• Main Authors: Ji-Cai, Wang, Liu, Fang, Yan-Jiao, Wang, Wen-Yu, Li, Xiu-Feng, Xu
• Format: Journal Article
• Language: Chinese
• Published: Chengdu Editorial Office of Sichuan Mental Health 01.01.2014
• Subjects: Mental depression
• ISSN: 1007-3256

ObjectiveThe aim of this study was to evaluate the efficacy and safety of duloxetine to the patients with depressive disorders.Methodsa randomized, double-blind, double-dummy, parallel controlled study was carried out between 5 1 patients who met the DSM-Ⅳcriteria of depression and depressed episode. The 25 of total patients were treated with duloxetine (40～60 mg·d^-1) and the others were treated with paroxetine (20mg·d^-1) for 8 weeks. The efficacy were assessed by Hamilton Depression Rating Scale(HAMD), Hamilton Anxiety Scale(HAMA), Montgomery Depression Rating Scale(MADRS), Sheehan Disability Scale(SDS) visual analogue scale(VAS-PI), Clinical Global Impression (CGI) and the safety was assessed by Adverse Event.ResultsAfter 8 weeks treatment, the total effective rates of duloxetine group and paroxetine group were 72.0%and 73.1% respectively, with no significant difference(P>0.05). The clinical curing rate of duloxetine group and paroxetine group were 20.0% and 23.1% respectively, with no significant differe